- Home
- XERS vs HFWA Comparison
XERS vs HFWA Comparison
Compare XERS & HFWA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | XERS | HFWA |
|---|---|---|
| Founded | 2005 | 1927 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2021 | 1997 |
Fundamental Metrics
Financial Performance| Metric | XERS | HFWA |
|---|---|---|
| Price | $6.28 | $27.43 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 4 |
| Target Price | $10.83 | ★ $30.50 |
| AVG Volume (30 Days) | ★ 1.2M | 219.4K |
| Earning Date | 05-07-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 3.53% |
| EPS Growth | ★ 100.00 | 58.06 |
| EPS | N/A | ★ 1.96 |
| Revenue | ★ $49,590,000.00 | N/A |
| Revenue This Year | $34.37 | $45.85 |
| Revenue Next Year | $22.86 | $7.83 |
| P/E Ratio | ★ N/A | $13.98 |
| Revenue Growth | ★ 142.67 | N/A |
| 52 Week Low | $4.30 | $21.32 |
| 52 Week High | $10.08 | $28.98 |
Technical Indicators
Market Signals| Indicator | XERS | HFWA |
|---|---|---|
| Relative Strength Index (RSI) | 56.56 | 54.81 |
| Support Level | $6.26 | $26.47 |
| Resistance Level | $6.41 | $28.52 |
| Average True Range (ATR) | 0.20 | 0.89 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 71.38 | 48.58 |
Price Performance
Historical ComparisonAbout XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
About HFWA Heritage Financial Corporation
Heritage Financial Corp is a bank holding company. The company, through its subsidiary, provides commercial lending and deposit relationships with small businesses and their owners in its market areas and attracts deposits from the general public. It accepts various deposit products, such as non-interest demand accounts, money market accounts, savings accounts, and certificates of deposit. Besides, the Bank also makes real estate construction loans, land development loans, and consumer loans, and originates first mortgage loans on residential properties mainly located in its market area. Geographically, all the business activity functions through the region of the United States.